A Phase 1 Study of LY2875358 in Patients With Advanced Cancer

Status
Active
Cancer Type
Non-Hodgkin Lymphoma
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01287546
Protocol IDs
13298 (primary)
I4C-MC-JTBA
Study Sponsor
Eli Lilly and Company

Summary

The objective of this study is to determine a recommended Phase 2 dose range of LY2875358 that may be safely administered to patients with advanced cancer. In Part A and Part A2 of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib will be evaluated for safety and tolerability, respectively. In Part B, LY2875358 monotherapy at maximum tolerated dose (MTD) will be explored in 3 different tumor types.

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Julia maloney
404-778-1805

Doctors:

Bradley C. Carthon, MD, PhD